These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

516 related articles for article (PubMed ID: 31470128)

  • 1. Combination Treatment of the Oral CHK1 Inhibitor, SRA737, and Low-Dose Gemcitabine Enhances the Effect of Programmed Death Ligand 1 Blockade by Modulating the Immune Microenvironment in SCLC.
    Sen T; Della Corte CM; Milutinovic S; Cardnell RJ; Diao L; Ramkumar K; Gay CM; Stewart CA; Fan Y; Shen L; Hansen RJ; Strouse B; Hedrick MP; Hassig CA; Heymach JV; Wang J; Byers LA
    J Thorac Oncol; 2019 Dec; 14(12):2152-2163. PubMed ID: 31470128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.
    Sen T; Rodriguez BL; Chen L; Corte CMD; Morikawa N; Fujimoto J; Cristea S; Nguyen T; Diao L; Li L; Fan Y; Yang Y; Wang J; Glisson BS; Wistuba II; Sage J; Heymach JV; Gibbons DL; Byers LA
    Cancer Discov; 2019 May; 9(5):646-661. PubMed ID: 30777870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma.
    Diggs LP; Ruf B; Ma C; Heinrich B; Cui L; Zhang Q; McVey JC; Wabitsch S; Heinrich S; Rosato U; Lai W; Subramanyam V; Longerich T; Loosen SH; Luedde T; Neumann UP; Desar S; Kleiner D; Gores G; Wang XW; Greten TF
    J Hepatol; 2021 May; 74(5):1145-1154. PubMed ID: 33276030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gemcitabine and checkpoint blockade exhibit synergistic anti-tumor effects in a model of murine lung carcinoma.
    Du B; Wen X; Wang Y; Lin M; Lai J
    Int Immunopharmacol; 2020 Sep; 86():106694. PubMed ID: 32570034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC.
    Taniguchi H; Caeser R; Chavan SS; Zhan YA; Chow A; Manoj P; Uddin F; Kitai H; Qu R; Hayatt O; Shah NS; Quintanal Villalonga Á; Allaj V; Nguyen EM; Chan J; Michel AO; Mukae H; de Stanchina E; Rudin CM; Sen T
    Cell Rep; 2022 May; 39(7):110814. PubMed ID: 35584676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action.
    Xue Y; Gao S; Gou J; Yin T; He H; Wang Y; Zhang Y; Tang X; Wu R
    Expert Opin Drug Deliv; 2021 Feb; 18(2):187-203. PubMed ID: 32954856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment.
    Fang DD; Tang Q; Kong Y; Wang Q; Gu J; Fang X; Zou P; Rong T; Wang J; Yang D; Zhai Y
    J Immunother Cancer; 2019 Nov; 7(1):327. PubMed ID: 31779710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade.
    Qin Y; Vasilatos SN; Chen L; Wu H; Cao Z; Fu Y; Huang M; Vlad AM; Lu B; Oesterreich S; Davidson NE; Huang Y
    Oncogene; 2019 Jan; 38(3):390-405. PubMed ID: 30111819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of PD-1/PD-L1 inhibitor plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small cell lung cancer: A systematic review and meta-analysis.
    Zhang S; Li S; Cheng Y
    Thorac Cancer; 2020 Dec; 11(12):3536-3546. PubMed ID: 33058504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
    Tanvetyanon T; Gray JE; Antonia SJ
    Expert Opin Biol Ther; 2017 Mar; 17(3):305-312. PubMed ID: 28064556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer.
    Jones R; Plummer R; Moreno V; Carter L; Roda D; Garralda E; Kristeleit R; Sarker D; Arkenau T; Roxburgh P; Walter HS; Blagden S; Anthoney A; Klencke BJ; Kowalski MM; Banerji U
    Clin Cancer Res; 2023 Jan; 29(2):331-340. PubMed ID: 36378548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of Immunotherapy in Extensive-Stage Small Cell Lung Cancer.
    Konala VM; Madhira BR; Ashraf S; Graziano S
    Oncology; 2020; 98(11):749-754. PubMed ID: 32663833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pancreatic cancer immune tumor microenvironment is negatively remodeled by gemcitabine while TGF-β receptor plus dual checkpoint inhibition maintains antitumor immune cells.
    Rana M; Kansal R; Chaib M; Teng B; Morrrison M; Hayes DN; Stanfill AG; Shibata D; Carson JA; Makowski L; Glazer ES
    Mol Carcinog; 2022 Jun; 61(6):549-557. PubMed ID: 35319799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of PD-1/PD-L1 Inhibitor Chemotherapy Combined with Lung Cancer Fang No. 1 in Relapsed and Refractory SCLC: A Retrospective Observational Study.
    Wang L; Lei X; Wang X
    Comput Math Methods Med; 2022; 2022():2848220. PubMed ID: 35586668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PI3Kγδ inhibitor plus radiation enhances the antitumour immune effect of PD-1 blockade in syngenic murine breast cancer and humanised patient-derived xenograft model.
    Han MG; Jang BS; Kang MH; Na D; Kim IA
    Eur J Cancer; 2021 Nov; 157():450-463. PubMed ID: 34601286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TNFR2 blockade alone or in combination with PD-1 blockade shows therapeutic efficacy in murine cancer models.
    Case K; Tran L; Yang M; Zheng H; Kuhtreiber WM; Faustman DL
    J Leukoc Biol; 2020 Jun; 107(6):981-991. PubMed ID: 32449229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of PD-1/PD-L1 Inhibitor and Chemotherapy in Treatment of Advanced Small Cell Lung Cancer.
    Tian W; Zhao J; Wang W; Li Y
    Altern Ther Health Med; 2024 Jul; 30(7):252-257. PubMed ID: 37971453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-PD-L1 immune checkpoint inhibitors in combination with etoposide and platinum for extensive-stage small cell lung cancer: a case report.
    Xue L; Chen B; Lin J; Peng J
    Ann Palliat Med; 2021 Jan; 10(1):828-835. PubMed ID: 33545805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.